Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2

Ch14.18 manufactured in Chinese hamster ovary (CHO) cells is currently being evaluated in clinical trials. Short-term infusion (STI) (8–20 h/day; 4–5 days) of 100 mg/m2 ch14.18/CHO (dinutiximab β) per cycle in combination with cytokines is standard treatment of neuroblastoma (NB) patients. As pain i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:MAbs
Autores principales: Siebert, Nikolai, Eger, Christin, Seidel, Diana, Jüttner, Madlen, Zumpe, Maxi, Wegner, Danilo, Kietz, Silke, Ehlert, Karoline, Veal, Gareth J., Siegmund, Werner, Weiss, Michael, Loibner, Hans, Ladenstein, Ruth, Lode, Holger N.
Formato: Artigo
Lenguaje:Inglês
Publicado: Taylor & Francis 2016
Materias:
Reports
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4966854/
https://ncbi.nlm.nih.gov/pubmed/26785755
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/19420862.2015.1130196
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares